MCID: INS024
MIFTS: 75

Insulin-Like Growth Factor I

Categories: Genetic diseases, Rare diseases, Endocrine diseases, Neuronal diseases, Ear diseases, Mental diseases

Aliases & Classifications for Insulin-Like Growth Factor I

MalaCards integrated aliases for Insulin-Like Growth Factor I:

Name: Insulin-Like Growth Factor I 54
Insulin-Like Growth Factor I, Resistance to 24 13 69
Insulin-Like Growth Factor I Deficiency 50 24 69
Insulin-Like Growth Factor 1 Resistance to 50 29
End-Organ Insensitivity to Somatomedin 24 71
Igf-I Resistance 24 52
Igf1 Deficiency 50 24
Growth Retardation with Sensorineural Deafness and Mental Retardation 50
Growth Delay Due to Insulin-Like Growth Factor I Resistance 56
Resistance to Insulin-Like Growth Factor 1 24
Resistance to Insulin-Like Growth Factor I 71
Insulin-Like Growth Factor 1 Deficiency 24
Insulin-Like Growth Factor 1 Resistance 71
Somatomedin End-Organ Insensitivity to 50
Somatomedin-C Resistance to 50
Resistance to Somatomedin-C 71
Resistance to Igf-1 56
Igf-1 Resistance 50
Igfi Resistance 24
Igf1 Resistance 71
Igf1res 71

Characteristics:

Orphanet epidemiological data:

56
growth delay due to insulin-like growth factor i resistance
Inheritance: Autosomal dominant,Autosomal recessive; Age of onset: Infancy,Neonatal;

OMIM:

54
Inheritance:
autosomal dominant
autosomal recessive

Miscellaneous:
onset in utero


HPO:

32
insulin-like growth factor i:
Onset and clinical course congenital onset
Inheritance autosomal recessive inheritance autosomal dominant inheritance


Classifications:

Orphanet: 56  
Rare endocrine diseases


Summaries for Insulin-Like Growth Factor I

NIH Rare Diseases : 50 the following summary is from orphanet, a european reference portal for information on rare diseases and orphan drugs.orpha number: 73273disease definitiongrowth delay due to igf-i resistance is characterised by variable intrauterine and postnatal growth retardation and elevated serum igf-i levels. addition features include variable degrees of intellectual deficit, microcephaly and dysmorphism (broad nasal bridge and tip, smooth philtrum, thin upper and everted lower lips, short fingers, clinodactyly, wide-set nipples and pectus excavatum).epidemiologyprevalence is unknown.etiologyigf-i resistance may be caused by a variety of genetic defects: ring chromosome 15, distal heterozygous 15q deletions encompassing the igf1r gene (15q26.3), or igf1r gene mutations. intellectual deficit is pronounced in patients with ring chromosome 15 but varies depending on the size of the deletion and on the functions of other deleted genes in patients with 15q deletions. partial igf-i insensitivity due to igf1r haploinsufficiency has been reported in one patient with a small deletion encompassing one allele of the igf1r gene and was characterised by small size for gestational age, persistent growth failure that improved considerably with gh therapy, and the absence of intellectual deficit. igf1r mutations have been described in six patients so far and were associated with variable growth delay and degrees of intellectual deficit.diagnostic methodsdiagnosis relies on karyotyping for detection of ring chromosome 15, detection of small deletions encompassing igf1r and detection of igf1r mutations by sequence variation screening methods or by direct sequencing of the 21 igf1r exons and their intron-exon junctions.differential diagnosisthe differential diagnosis should include bio-inactive igf-i resulting in igf-i deficiency (see this term). measurement of igf-i levels can be used for diagnosis but circulating levels of igf-i may vary over time for the same patient and may not be elevated in case of poor nutritional status.antenatal diagnosisprenatal diagnosis has not been reported and is complicated by the variable expressivity (even within the same family) of some of the reported mutations, especially in terms of their impact on intellectual development.genetic counselingin all but one of these patients, the mutations were heterozygous and transmitted as an autosomal dominanttrait. affected families should be offered genetic counselling and informed of a 50% risk of recurrence for dominant inheritance and of a 25% risk of recurrence for recessive transmission.management and treatmentmanagement involves nutritional and developmental support. although deafness has not yet been reported in patients with igf-i resistance, it is present in some patients with igf-i deficiency (caused by mutations in the gene encoding the igf1r ligand, igfi). as a result, screening for deafness should be proposed for all patients with igf-i resistance. some patients with igf-i resistance show increased growth velocity with recombinant gh therapy while others show no response.prognosisprognosis varies depending on the underlying molecular anomaly.visit the orphanet disease page for more resources. last updated: 5/22/2008

MalaCards based summary : Insulin-Like Growth Factor I, also known as insulin-like growth factor i, resistance to, is related to kowarski syndrome and prostate cancer, and has symptoms including short stature, microcephaly and intrauterine growth retardation. An important gene associated with Insulin-Like Growth Factor I is IGF1R (Insulin Like Growth Factor 1 Receptor), and among its related pathways/superpathways are Apoptotic Pathways in Synovial Fibroblasts and ERK Signaling. The drugs Clonidine and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and prostate, and related phenotypes are Decreased viability and growth/size/body region

UniProtKB/Swiss-Prot : 71 Insulin-like growth factor 1 resistance: A disorder characterized by intrauterine growth retardation, poor postnatal growth and increased plasma IGF1 levels.

Description from OMIM: 270450

Related Diseases for Insulin-Like Growth Factor I

Diseases related to Insulin-Like Growth Factor I via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 287)
id Related Disease Score Top Affiliating Genes
1 kowarski syndrome 32.9 GH1 GHR IGF1
2 prostate cancer 29.1 AKT1 AKT2 EGF IGF1 IGF1R IGF2
3 growth retardation with deafness and mental retardation due to igf1 deficiency 11.9
4 laron dwarfism 11.5
5 growth hormone insensitivity with immunodeficiency 11.4
6 acid-labile subunit, deficiency of 11.1
7 oxyphilic adenoma 10.9 IGF1 IRS1
8 intellectual deficit buenos-aires type 10.9 INS INSR
9 selenium poisoning 10.9 IGF1 IGFBP3 INS
10 small cell lung cancer, childhood 10.9 IGF1 IGFBP3
11 lipase deficiency, combined 10.9 GH1 IGF1 IGFBP3
12 pituitary adenoma, prolactin-secreting 10.9 GH1 IGF1 IGFBP3
13 condrodisplasia punctata rizomélica 10.8 IGF2 IGFBP2 IGFBP3
14 febrile infection-related epilepsy syndrome 10.8 IGF1 IGF2 INSR
15 algoneurodystrophy 10.8 IGF1 IGF2 INS
16 breast cancer 10.8
17 acyl-coa dehydrogenase, short-chain, deficiency of 10.8 GHR IGF1
18 pediatric osteosarcoma 10.8 GHR IGF1R IGFBP2 IGFBP3
19 radioulnar synostosis with amegakaryocytic thrombocytopenia 1 10.8 GH1 GHR IGF1 IGFBP3
20 primary hypomagnesemia 10.8 GH1 GHR IGF1
21 urogenital tuberculosis 10.8 IGF1 IGFBP2
22 mucinoses 10.8 IGF1R INS INSR
23 molybdenum cofactor deficiency b 10.8 GH1 GHR IGF1
24 chondroma 10.8 IGF1 IGF2 INS
25 pericardial tuberculosis 10.8 IGF1 IGF2 IGFBP3 INS
26 uterine ligament clear cell adenocarcinoma 10.8 GH1 IGF1 INS
27 allergic asthma 10.8 GH1 IGF1 IGFBP3 INS
28 capillary lymphangioma 10.8 GH1 IGF1 INS
29 pelvic muscle wasting 10.8 IGF1 IGFBP1 INS INSR
30 tinea unguium 10.7 IGFBP1 IGFBP4 IGFBP5
31 aromatic l-amino acid decarboxylase deficiency 10.7 IGF1 IGF2 IGFBP1 IGFBP3
32 grubben de cock borghgraef syndrome 10.7 GH1 IGF1 IGFBP3
33 neurogenic arthropathy 10.7 IGF1 IGF2 INS IRS1
34 prostatitis 10.7
35 diabetic cataract 10.7 IGF2 INS INSR
36 small cell cancer of the lung, somatic 10.7 IGF1 IGF1R IGF2 IGFBP5
37 hyperlipoproteinemia, type ib 10.7 IGF1 IGF1R IGFBP3 INS INSR
38 bile duct signet ring cell carcinoma 10.7 GH1 GHR IGF1 IGFBP1 IGFBP3
39 haverhill fever 10.7 EGF IGF1 IGF2
40 protein s deficiency 10.7 GH1 GHR IGF1 IGFBP3 INS
41 peroneal neuropathy 10.7 IGF1 INS INSR IRS1
42 exostosis 10.7 IGF1 IGFBP1 IGFBP3 INS INSR
43 simple cryoglobulinemia 10.7 GH1 GHR
44 growth hormone insensitivity, partial 10.6 GH1 GHR IGF1 IGF2 IGFBP3
45 bardet-biedl syndrome 10.6 AKT1 EGF IGF1 IGFBP3
46 hypertrichosis 10.6 AKT1 IGF1 INS IRS1
47 medullomyoblastoma 10.6 AKT1 IGF1 IGFBP3
48 fetal parvovirus syndrome 10.6 IGF1 IGF2 IGFBP3 INS INSR
49 survival motor neuron spinal muscular atrophy 10.6 AKT1 IGF1 INS IRS1
50 short bowel syndrome 10.6 IGF1 IGFBP1 INS INSR IRS1

Graphical network of the top 20 diseases related to Insulin-Like Growth Factor I:



Diseases related to Insulin-Like Growth Factor I

Symptoms & Phenotypes for Insulin-Like Growth Factor I

Symptoms via clinical synopsis from OMIM:

54

Growth- Height:
short stature

Skeletal:
delayed bone age

Growth- Other:
intrauterine growth retardation
poor growth

Chest- Breasts:
widely spaced nipples

Skeletal- Hands:
clinodactyly

Chest- External Features:
pectus excavatum

Head And Neck- Face:
long, smooth philtrum
facial dysmorphism (in some patients)
receding hairline

Neurologic- Central Nervous System:
delayed motor development
speech delay

Head And Neck- Head:
microcephaly

Growth- Weight:
low weight

Head And Neck- Mouth:
thin upper lip
fleshy lower lip

Head And Neck- Nose:
broad nasal bridge

Neurologic- Behavioral Psychiatric Manifestations:
agitation
anxious affect
obsessive tendencies

Laboratory- Abnormalities:
increased serum insulin-like growth factor-1 (igf1, )
increased or normal serum growth hormone (gh, )


Clinical features from OMIM:

270450

Human phenotypes related to Insulin-Like Growth Factor I:

56 32 (show all 26)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 short stature 56 32 hallmark (90%) Very frequent (99-80%) HP:0004322
2 microcephaly 56 32 frequent (33%) Frequent (79-30%) HP:0000252
3 intrauterine growth retardation 56 32 hallmark (90%) Very frequent (99-80%) HP:0001511
4 broad nasal tip 56 32 frequent (33%) Frequent (79-30%) HP:0000455
5 intellectual disability 56 32 frequent (33%) Frequent (79-30%) HP:0001249
6 thin vermilion border 56 32 frequent (33%) Frequent (79-30%) HP:0000233
7 clinodactyly 56 32 frequent (33%) Frequent (79-30%) HP:0030084
8 wide nasal bridge 56 32 frequent (33%) Frequent (79-30%) HP:0000431
9 pectus excavatum 56 32 frequent (33%) Frequent (79-30%) HP:0000767
10 motor delay 56 32 frequent (33%) Frequent (79-30%) HP:0001270
11 smooth philtrum 56 32 frequent (33%) Frequent (79-30%) HP:0000319
12 delayed skeletal maturation 56 32 hallmark (90%) Very frequent (99-80%) HP:0002750
13 everted lower lip vermilion 56 32 frequent (33%) Frequent (79-30%) HP:0000232
14 short palm 56 32 frequent (33%) Frequent (79-30%) HP:0004279
15 wide intermamillary distance 56 32 frequent (33%) Frequent (79-30%) HP:0006610
16 long philtrum 32 HP:0000343
17 agitation 32 HP:0000713
18 anxiety 32 HP:0000739
19 thin upper lip vermilion 32 HP:0000219
20 delayed speech and language development 32 HP:0000750
21 growth delay 56 Very frequent (99-80%)
22 abnormal facial shape 32 HP:0001999
23 decreased body weight 32 HP:0004325
24 radial deviation of finger 32 HP:0009466
25 increased serum insulin-like growth factor 1 {comment="hpo 32 HP:0030269
26 abnormality of the rib cage 32 HP:0001547

UMLS symptoms related to Insulin-Like Growth Factor I:


agitation

GenomeRNAi Phenotypes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.5 ITGB3
2 Decreased viability GR00221-A-1 10.5 IGF1R INSR IRS1 AKT1 AKT2
3 Decreased viability GR00221-A-2 10.5 IGF1R INSR IRS1 AKT1 ITGB3 ITGAV
4 Decreased viability GR00221-A-3 10.5 AKT2 IGF1R INSR AKT1
5 Decreased viability GR00221-A-4 10.5 AKT2 INSR AKT1 ITGB3
6 Decreased viability GR00301-A 10.5 AKT2 IGF1R
7 Decreased viability GR00342-S-2 10.5 IGF1R IRS1
8 Decreased viability GR00342-S-3 10.5 AKT2 IRS1
9 Decreased viability GR00381-A-1 10.5 ITGAV
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.19 GH1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-142 10.19 INSR
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.19 IGF1R
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.19 IGF1R
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 10.19 GH1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.19 INSR
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.19 AKT1 INSR
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.19 AKT2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.19 INSR
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.19 AKT1 AKT2 GH1 IGF1R INSR
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.19 INSR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.19 IGF1R
22 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 AKT2 IGF1R IRS1 ITGA6 ITGAV ITGB3
23 Increased cell death HMECs cells GR00103-A-0 9.5 INSR IRS1 ITGAV IGF1R IGFBP4 IGFBP6
24 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AKT1 AKT2 IGF1R INSR

MGI Mouse Phenotypes related to Insulin-Like Growth Factor I:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.44 IGFBP5 INS INSR IRS1 ITGA6 ITGAV
2 endocrine/exocrine gland MP:0005379 10.42 AKT1 AKT2 EGF GHR IGF1 IGF1R
3 cellular MP:0005384 10.39 AKT1 AKT2 GHR IGF1 IGF1R IGF2
4 immune system MP:0005387 10.37 AKT1 AKT2 EGF GHR IGF1 IGF1R
5 cardiovascular system MP:0005385 10.36 INSR IRS1 ITGA6 ITGAV ITGB3 AKT1
6 homeostasis/metabolism MP:0005376 10.36 AKT1 AKT2 GHR IGF1 IGF1R IGF2
7 hematopoietic system MP:0005397 10.34 IGF1 IGF1R IGF2 IGFBP2 INS INSR
8 adipose tissue MP:0005375 10.33 AKT1 AKT2 GHR IGF1 IGF1R IGFBP3
9 muscle MP:0005369 10.25 IGF1R IGF2 IGFBP3 IGFBP4 IGFBP5 INS
10 integument MP:0010771 10.22 INS ITGA6 ITGB3 AKT1 AKT2 EGF
11 liver/biliary system MP:0005370 10.21 IGF1R IGF2 IGFBP1 IGFBP2 IGFBP3 INS
12 digestive/alimentary MP:0005381 10.17 ITGA6 ITGAV ITGB3 EGF IGF1R IGF2
13 embryo MP:0005380 10.16 IGF1R IGF2 INS ITGA6 ITGAV ITGB3
14 nervous system MP:0003631 10.06 AKT1 AKT2 GHR IGF1 IGF1R IGF2
15 limbs/digits/tail MP:0005371 9.93 GHR IGF1 IGF1R IGF2 IRS1 ITGA6
16 neoplasm MP:0002006 9.91 AKT1 AKT2 IGF1 IGF1R ITGA6 ITGAV
17 renal/urinary system MP:0005367 9.91 GHR IGF1 IGF2 IGFBP2 INS INSR
18 reproductive system MP:0005389 9.85 AKT1 AKT2 EGF GHR IGF1 IGF1R
19 respiratory system MP:0005388 9.56 INSR ITGA6 ITGB3 AKT1 AKT2 IGF1
20 skeleton MP:0005390 9.28 AKT1 AKT2 GHR IGF1 IGF1R IGF2

Drugs & Therapeutics for Insulin-Like Growth Factor I

Drugs for Insulin-Like Growth Factor I (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 503)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clonidine Approved Phase 4,Phase 2,Phase 3 4205-90-7 2803
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-28-2 5757
3
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
4
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
5
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Tibolone Approved Phase 4 5630-53-5
8 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
9
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
10
Insulin Aspart Approved Phase 4 116094-23-6 16132418
11
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
12
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
13
Fosinopril Approved Phase 4 98048-97-6 55891
14
Sodium oxybate Approved Phase 4 502-85-2 5360545
15
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
16
Topiramate Approved Phase 4 97240-79-4 5284627
17
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
18
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
19
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 3 57-63-6 5991
20
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3 51-43-4 5816
21 Racepinephrine Approved Phase 4,Phase 2,Phase 3
22
Insulin Detemir Approved Phase 4,Phase 3 169148-63-4 5311023
23
Citalopram Approved Phase 4 59729-33-8 2771
24
Vortioxetine Approved Phase 4 508233-74-7 9966051
25
Letrozole Approved, Investigational Phase 4,Phase 2 112809-51-5 3902
26
Desogestrel Approved Phase 4 54024-22-5 40973
27
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
28
Norelgestromin Approved Phase 4 53016-31-2 13752005
29
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
30
Liraglutide Approved Phase 4 204656-20-2 44147092
31
Verapamil Approved Phase 4 52-53-9 2520
32
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
33
Dehydroepiandrosterone Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 53-43-0 9860744
34
gamma-Aminobutyric acid Investigational Phase 4 56-12-2 119
35 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
36 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
38 Imatinib Mesylate Phase 4 123596
39 Complement Factor I Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
40 insulin Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Insulin, Globin Zinc Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Mitogens Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
43 Adrenergic Agents Phase 4,Phase 2,Phase 3
44 Adrenergic Agonists Phase 4,Phase 2,Phase 3
45 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3
46 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3
47 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
48 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Phase 1
49 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1
50 Contraceptive Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 719)

id Name Status NCT ID Phase Drugs
1 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
2 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
3 Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
4 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
5 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
6 Effect of Growth Hormone in Metabolic Syndrome Unknown status NCT00307411 Phase 4 Growth hormone
7 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
8 Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD. Completed NCT02092584 Phase 4
9 Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study) Completed NCT00710307 Phase 4
10 IGF1 Generation Test Completed NCT00145457 Phase 4
11 The Effect of Ophiocephalus Striatus Extract on Levels of IGF-1, Albumin, and MNA Score in Elderly With Malnutrition Completed NCT03065595 Phase 4
12 A Study to Optimize Growth Hormone Dosing in Children With Chronic Kidney Disease by Measuring IGF-1 Levels in Blood Completed NCT00212758 Phase 4 Nutropin AQ
13 Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat Completed NCT00991926 Phase 4 Orlistat
14 Study to Compare the Effect of Hormone Replacement Therapy (HRT) on Breast and Cardiovascular Metabolic Markers in Postmenopausal Women Completed NCT00145522 Phase 4 17ß-Estradiol/Dydrogesterone;Tibolone
15 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
16 Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients Completed NCT01209403 Phase 4 Glucose-infusion;Glucose-insulin infusion
17 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
18 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
19 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
20 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
21 GH and Cardiovascular Risk Factors Completed NCT01877512 Phase 4 Change in daily dosage of Growth Hormone
22 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
23 Angiotensin-converting Enzyme (ACE)-Inhibition and Mechanisms of Skeletal Muscle Weakness in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01014338 Phase 4 Fosinopril
24 Predictive Markers in Chinese Growth Hormone Deficiency (GHD) Children Treated With Saizen® Completed NCT01187550 Phase 4 Recombinant human growth hormone (r-hGH)
25 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
26 Predictive Markers in GHD and TS Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen
27 Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles Completed NCT02866253 Phase 4 DHEA
28 Exploratory Clinical Study to Evaluate Sodium Oxybate (Xyrem) on Potential Endocrine Changes Completed NCT00345800 Phase 4 Sodium Oxybate (Xyrem)
29 Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature Completed NCT00458263 Phase 4 Somatotropin growth hormone recombinant human
30 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
31 Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients Completed NCT01562834 Phase 4 somatropin;placebo
32 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
33 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
34 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
35 A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy Completed NCT01030094 Phase 4 Topiramate;Carbamazepine;Valproic acid;Normal control
36 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4
37 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
38 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
39 Cognitive Dysfunction in MDD Patients Recruiting NCT03187093 Phase 4 Vortioxetine;Escitalopram
40 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT02976675 Phase 4
41 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency Recruiting NCT03249480 Phase 4
42 Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency Recruiting NCT02908958 Phase 4
43 Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children Recruiting NCT03290235 Phase 4 PEG-somatropin
44 Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole Recruiting NCT02137538 Phase 4 Letrozole;Anastrozole
45 Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis Active, not recruiting NCT02367833 Phase 4 Combined Oral Contraceptive;Transdermal Contraceptive;Contraceptive Vaginal Ring
46 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
47 A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency Active, not recruiting NCT02311894 Phase 4 Somatropin
48 Assessing the Impact of Contraceptives on Bone Health Using 41Ca Active, not recruiting NCT02367846 Phase 4 Combined Oral Contraceptive (COC);Contraceptive Vaginal Ring (CVR)
49 The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders Active, not recruiting NCT02357472 Phase 4 dehydroepiandrosterone
50 The Health Influences of Puberty (HIP) Study Active, not recruiting NCT01775813 Phase 4 Metformin

Search NIH Clinical Center for Insulin-Like Growth Factor I

Genetic Tests for Insulin-Like Growth Factor I

Genetic tests related to Insulin-Like Growth Factor I:

id Genetic test Affiliating Genes
1 Insulin-Like Growth Factor 1 Resistance to 29
2 Insulin-Like Growth Factor I, Resistance to 24 IGF1R

Anatomical Context for Insulin-Like Growth Factor I

MalaCards organs/tissues related to Insulin-Like Growth Factor I:

39
Breast, Bone, Prostate, Lung, Liver, Pituitary, Heart

Publications for Insulin-Like Growth Factor I

Articles related to Insulin-Like Growth Factor I:

(show top 50) (show all 2628)
id Title Authors Year
1
First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I. ( 28110155 )
2017
2
A role for astrocytes in cerebellar deficits in frataxin deficiency: Protection by insulin-like growth factor I. ( 28286293 )
2017
3
Serum insulin-like growth factor-I levels are associated with improved white matter recovery after traumatic brain injury. ( 28574152 )
2017
4
Effect of pre- and postpartum supplementation with lipid-encapsulated conjugated linoleic acid on reproductive performance and the growth hormone-insulin-like growth factor-I axis in multiparous high-producing dairy cows. ( 28456404 )
2017
5
Standardization of Growth Hormone and Insulin-like Growth Factor-I Measurements. ( 28516748 )
2017
6
Feed restriction and insulin-like growth factor-I (IGF-I) affect the oocyte maturation in matrinxAL Brycon amazonicus. ( 27928979 )
2017
7
Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium. ( 28205047 )
2017
8
Growth and Growth hormone - Insulin Like Growth Factor -I (GH-IGF-I) Axis in Chronic Anemias. ( 28467344 )
2017
9
PEGylated insulin-like growth factor-I affords protection and facilitates recovery of lost functions post-focal ischemia. ( 28325900 )
2017
10
Insulin-like growth factor I and its binding protein-3 are regulators of lactation and maternal responsiveness. ( 28611445 )
2017
11
Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. ( 27870006 )
2017
12
Feeling misguided: a comment on the US guidelines on growth hormone and insulin-like growth factor-I treatment in children and adolescents. ( 28604412 )
2017
13
The role of insulin-like growth factor I-II receptor on development of pleomorphic adenoma. ( 28625007 )
2017
14
Retraction: Targeting 3-Phosphoinoside-Dependent Kinase-1 to Inhibit Insulin-Like Growth Factor-I Induced AKT and p70 S6 Kinase Activation in Breast Cancer Cells. ( 28394928 )
2017
15
Insulin-like growth factor I enhances the developmental competence of yak embryos by modulating aquaporin 3. ( 28512855 )
2017
16
Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk. ( 28478612 )
2017
17
Rejuvenating Effect of Long-Term Insulin-Like Growth Factor-I Gene Therapy in the Hypothalamus of Aged Rats with Dopaminergic Dysfunction. ( 28673122 )
2017
18
Serum reference value of two potential doping candidates-myostatin and insulin-like growth factor-I in the healthy young male. ( 28077934 )
2017
19
Decreased Serum Insulin-like Growth Factor-I is a Risk Factor for Non-vertebral Fractures in Diabetic Postmenopausal Women. ( 28154269 )
2017
20
Addition of insulin-like growth factor I to the maturation medium of bovine oocytes subjected to heat shock: effects on the production of reactive oxygen species, mitochondrial activity and oocyte competence. ( 28445838 )
2017
21
To Prime or Not to Prime - Is That Still a Question? A Comment on the US Guidelines on Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents. ( 28505613 )
2017
22
A Coordinated Action of Blood-Borne and Brain Insulin-Like Growth Factor I in the Response to Traumatic Brain Injury. ( 28449086 )
2017
23
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. ( 28678199 )
2017
24
Is insulin-like growth factor-I a good marker for treatment adherence in growth hormone deficiency in adulthood? ( 26824335 )
2016
25
A Concerted Action Of Estradiol And Insulin Like Growth Factor I Underlies Sex Differences In Mood Regulation By Exercise. ( 27170462 )
2016
26
Ghrelin, insulin-like growth factor I and adipocytokines concentrations in born small for gestational age prepubertal children after the catch-up growth. ( 27269893 )
2016
27
Defining human insulin-like growth factor I gene regulation. ( 27406741 )
2016
28
Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice. ( 26932768 )
2016
29
Clinical Evaluation of Insulin like Growth Factor-I and Vascular Endothelial Growth Factor with Alloplastic Bone Graft Material in the Management of Human Two Wall Intra-Osseous Defects. ( 27790578 )
2016
30
Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells. ( 27639384 )
2016
31
Insulin-Like Growth Factor I Receptor (IGF-IR) Ligands and BMI in Squamous Intra-Epithelial Lesion (SIL) of Cervix. ( 27042445 )
2016
32
Brain insulin-like growth factor-I directs the transition from stem cells to mature neurons during postnatal/adult hippocampal neurogenesis. ( 27144663 )
2016
33
Association of insulin-like growth factor-I with the severity and outcomes of acute ischemic stroke. ( 28435630 )
2016
34
Astrocyte Resilience to Oxidative Stress Induced by Insulin-like Growth Factor I (IGF-I) Involves Preserved AKT (Protein Kinase B) Activity. ( 26631726 )
2016
35
POSTNATAL SERUM INSULIN-LIKE GROWTH FACTOR I AND RETINOPATHY OF PREMATURITY. ( 27529840 )
2016
36
Incidence of apoptosis after retinoids and insulin-like growth factor-I (IGF-I) supplementation during goat in vitro embryo production. ( 27587268 )
2016
37
Survivin as a Novel Biomarker in the Pathogenesis of Acne Vulgaris and Its Correlation to Insulin-Like Growth Factor-I. ( 27803511 )
2016
38
High-intensity interval training (HIIT) increases insulin-like growth factor-I (IGF-I) in sedentary aging men but not masters' athletes: an observational study. ( 28042739 )
2016
39
Treatment with recombinant human insulin-like growth factor-I improves growth in patients with PAPP-A2 deficiency. ( 27648969 )
2016
40
Prognostic significance of insulin-like growth factor-I serum levels in acute decompensation of cirrhosis. ( 27775431 )
2016
41
The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies. ( 27444280 )
2016
42
Differential roles of the insulin and insulin-like growth factor-I (IGF-I) receptors in response to insulin and IGF-I. ( 27742877 )
2016
43
Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-I: A Novel Cellular Therapy for Alzheimer's Disease. ( 26744412 )
2016
44
Lower circulating insulin-like growth factor-I is associated with better cognition in females with exceptional longevity without compromise to muscle mass and function. ( 27744417 )
2016
45
The insulin-like growth factor I receptor regulates glucose transport by astrocytes. ( 27462832 )
2016
46
Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes. ( 26888146 )
2016
47
Rearing Mozambique tilapia in tidally-changing salinities: Effects on growth and the growth hormone/insulin-like growth factor I axis. ( 27032617 )
2016
48
Serum Insulin-like Growth Factor I Quantitation by Mass Spectrometry: Insights for Protein Quantitation with this Technology. ( 28149264 )
2016
49
Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. ( 27884013 )
2016
50
Insulin-like growth factor-I serum levels and their biological effects on Leishmania isolates from different clinical forms of American tegumentary leishmaniasis. ( 27286813 )
2016

Variations for Insulin-Like Growth Factor I

UniProtKB/Swiss-Prot genetic disease variations for Insulin-Like Growth Factor I:

71
id Symbol AA change Variation ID SNP ID
1 IGF1R p.Arg138Gln VAR_034891 rs121912426
2 IGF1R p.Lys145Asn VAR_034892 rs121912427
3 IGF1R p.Arg739Gln VAR_034895 rs121912429
4 IGF1R p.Asn359Tyr VAR_076247
5 IGF1R p.Tyr865Cys VAR_076248
6 IGF1R p.Arg1256Ser VAR_076249
7 IGF1R p.Arg1337Cys VAR_076250 rs141802822

ClinVar genetic disease variations for Insulin-Like Growth Factor I:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 IGF1 IGF1, EX4-5DEL deletion Pathogenic
2 IGF1 IGF1, MUTATION IN POLYADENYLATION SIGNAL, T-A single nucleotide variant Pathogenic
3 IGF1 NM_001111284.1(IGF1): c.226G> A (p.Val76Met) single nucleotide variant Pathogenic rs121912430 GRCh37 Chromosome 12, 102813415: 102813415
4 IGF1R NM_000875.4(IGF1R): c.413G> A (p.Arg138Gln) single nucleotide variant protective rs121912426 GRCh37 Chromosome 15, 99251109: 99251109
5 IGF1R NM_000875.4(IGF1R): c.435A> C (p.Lys145Asn) single nucleotide variant protective rs121912427 GRCh37 Chromosome 15, 99251131: 99251131
6 IGF1R NM_000875.4(IGF1R): c.265C> T (p.Arg89Ter) single nucleotide variant protective rs121912428 GRCh37 Chromosome 15, 99250961: 99250961
7 IGF1R NM_000875.4(IGF1R): c.2216G> A (p.Arg739Gln) single nucleotide variant protective rs121912429 GRCh37 Chromosome 15, 99465391: 99465391
8 IGF1R NM_000875.4(IGF1R): c.1532G> A (p.Arg511Gln) single nucleotide variant protective rs33958176 GRCh37 Chromosome 15, 99454613: 99454613
9 IGF1 NM_001111283.2(IGF1): c.292C> T (p.Arg98Trp) single nucleotide variant Pathogenic rs587779350 GRCh37 Chromosome 12, 102813397: 102813397
10 IGF1R NM_001291858.1(IGF1R): c.3184-2A> T single nucleotide variant Likely pathogenic rs886042346 GRCh37 Chromosome 15, 99478543: 99478543

Expression for Insulin-Like Growth Factor I

Search GEO for disease gene expression data for Insulin-Like Growth Factor I.

Pathways for Insulin-Like Growth Factor I

Pathways related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 104)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 AKT1 AKT2 EGF GH1 IGF1 IGF1R
2
Show member pathways
13.95 AKT1 AKT2 EGF GH1 IGF1 IGF1R
3
Show member pathways
13.89 GH1 IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3
4
Show member pathways
13.82 AKT1 AKT2 EGF GH1 IGF1 IGF1R
5
Show member pathways
13.64 AKT1 AKT2 EGF GH1 IGF1 IGF1R
6
Show member pathways
13.56 AKT1 AKT2 EGF GH1 GHR IGF1
7
Show member pathways
13.47 AKT1 AKT2 EGF GH1 IGF1 IGF1R
8
Show member pathways
13.42 AKT1 AKT2 EGF IGF1 IGF2 ITGA6
9
Show member pathways
13.4 AKT1 EGF GH1 IGF1 IGF1R IGF2
10
Show member pathways
13.38 AKT1 AKT2 EGF GH1 IGF1 IGF1R
11
Show member pathways
13.36 AKT1 EGF GH1 IGF1 IGF1R IGF2
12
Show member pathways
13.32 AKT1 AKT2 EGF GH1 GHR IGF1
13
Show member pathways
13.17 AKT1 EGF GH1 IGF1 IGF1R IGF2
14
Show member pathways
13.15 AKT1 AKT2 EGF GH1 IGF1 IGF1R
15
Show member pathways
13.1 IGF1 IGF1R IGF2 INSR ITGA6 ITGAV
16
Show member pathways
13.02 AKT1 AKT2 EGF IGF1 IGF1R ITGA6
17
Show member pathways
12.93 AKT1 AKT2 IGF1 IGF1R IGF2 INSR
18
Show member pathways
12.92 AKT1 INS INSR IRS1 ITGA6 ITGAV
19
Show member pathways
12.88 AKT1 AKT2 IGF1 IGF1R IGF2
20
Show member pathways
12.86 AKT1 AKT2 INS INSR IRS1
21
Show member pathways
12.86 AKT1 AKT2 EGF IGF1 IGF1R INS
22
Show member pathways
12.83 AKT1 AKT2 EGF INS INSR IRS1
23
Show member pathways
12.83 AKT1 AKT2 EGF GH1 GHR IGF1
24 12.8 AKT1 AKT2 EGF IGF1 IGF1R ITGA6
25
Show member pathways
12.78 AKT1 EGF GH1 IGF1 IGF2
26 12.72 EGF INS ITGA6 ITGAV ITGB3
27
Show member pathways
12.69 AKT1 AKT2 EGF IGF1 IGF1R IRS1
28
Show member pathways
12.65 AKT1 AKT2 EGF IGF1 IGF1R INS
29
Show member pathways
12.65 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
30
Show member pathways
12.64 AKT1 AKT2 IGF1R INS INSR IRS1
31
Show member pathways
12.64 AKT1 AKT2 IGF1 IGF1R INS INSR
32
Show member pathways
12.59 AKT1 AKT2 GH1 INS IRS1
33
Show member pathways
12.57 AKT1 AKT2 IGF1 IGF1R INS INSR
34
Show member pathways
12.55 AKT1 AKT2 IGF1R INSR ITGAV
35
Show member pathways
12.51 AKT1 AKT2 EGF INS INSR
36 12.5 AKT1 AKT2 EGF GH1 GHR IGF1
37
Show member pathways
12.49 EGF ITGA6 ITGAV ITGB3
38 12.49 AKT1 AKT2 IGF1R IGFBP1 IGFBP2 IGFBP3
39
Show member pathways
12.47 AKT1 AKT2 ITGAV ITGB3
40
Show member pathways
12.45 AKT1 AKT2 IGF1 IGF1R INS
41
Show member pathways
12.45 AKT1 AKT2 EGF IGF1 IGF1R INSR
42
Show member pathways
12.42 AKT1 IRS1 ITGA6 ITGAV
43 12.42 AKT1 AKT2 IGF1 IGF1R IGF2 ITGAV
44
Show member pathways
12.39 AKT1 AKT2 IGF1R INSR ITGA6 ITGAV
45
Show member pathways
12.38 AKT1 AKT2 IGF1 IGF1R IRS1
46
Show member pathways
12.33 AKT1 AKT2 INS INSR IRS1
47
Show member pathways
12.32 AKT1 AKT2 ITGAV ITGB3
48
Show member pathways
12.3 AKT1 AKT2 GH1 GHR
49
Show member pathways
12.29 AKT1 AKT2 EGF IGF1 IGF1R
50
Show member pathways
12.27 AKT1 AKT2 IGF1 IGF1R IGF2 IRS1

GO Terms for Insulin-Like Growth Factor I

Cellular components related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.89 IGFBP1 IGFBP3 IGFBP4 IGFBP5 INS
2 receptor complex GO:0043235 9.77 EGF GHR IGF1R INSR ITGB3
3 ruffle membrane GO:0032587 9.7 AKT2 ITGAV ITGB3
4 platelet alpha granule lumen GO:0031093 9.69 EGF IGF1 IGF2
5 integrin complex GO:0008305 9.63 ITGA6 ITGAV ITGB3
6 insulin receptor complex GO:0005899 9.48 INSR IRS1
7 growth hormone receptor complex GO:0070195 9.43 GH1 GHR
8 integrin alphav-beta3 complex GO:0034683 9.4 ITGAV ITGB3
9 insulin-like growth factor ternary complex GO:0042567 9.33 IGF1 IGFBP3 IGFBP5
10 insulin-like growth factor binding protein complex GO:0016942 9.13 IGF1 IGFBP3 IGFBP5
11 alphav-beta3 integrin-IGF-1-IGF1R complex GO:0035867 8.92 IGF1 IGF1R ITGAV ITGB3
12 extracellular region GO:0005576 10.1 EGF GH1 GHR IGF1 IGF2 IGFBP1
13 extracellular space GO:0005615 10 EGF GH1 GHR IGF1 IGF2 IGFBP1

Biological processes related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
id Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.98 EGF IGF1 IGF2 ITGB3
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.98 EGF GH1 GHR IGF1 IGF2 INS
3 activation of MAPK activity GO:0000187 9.97 EGF GHR IGF1 INSR
4 phosphatidylinositol-mediated signaling GO:0048015 9.97 AKT1 EGF IGF1 IGF1R IRS1
5 glucose homeostasis GO:0042593 9.97 AKT1 IGFBP5 INS INSR IRS1
6 positive regulation of protein kinase B signaling GO:0051897 9.95 IGF2 IGFBP5 INS INSR
7 cellular response to insulin stimulus GO:0032869 9.95 AKT1 AKT2 GHR INSR IRS1
8 regulation of growth GO:0040008 9.93 IGFBP2 IGFBP3 IGFBP4 IGFBP5
9 regulation of cell growth GO:0001558 9.93 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
10 glucose metabolic process GO:0006006 9.92 AKT1 AKT2 IGF2 IGFBP5 INS
11 positive regulation of MAPK cascade GO:0043410 9.91 IGF1 IGF2 IGFBP3 IGFBP4 INS INSR
12 cellular protein metabolic process GO:0044267 9.91 IGF1 IGF2 IGFBP1 IGFBP2 IGFBP3 IGFBP4
13 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.9 AKT1 EGF IRS1
14 positive regulation of cell growth GO:0030307 9.9 AKT1 IGFBP1 INS
15 cellular response to organic cyclic compound GO:0071407 9.9 AKT1 IGFBP5 ITGA6
16 regulation of cell migration GO:0030334 9.9 AKT1 AKT2 ITGB3
17 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.89 GH1 IGF1 INS
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 GH1 GHR IGF1
19 positive regulation of mitotic nuclear division GO:0045840 9.89 EGF IGF1 IGF2 INS INSR
20 positive regulation of DNA replication GO:0045740 9.88 IGF1 IGF1R INS INSR
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 AKT1 INS INSR
22 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.86 IGF1 ITGA6 ITGAV
23 phosphatidylinositol 3-kinase signaling GO:0014065 9.86 AKT1 IGF1 IGF1R IRS1
24 positive regulation of activated T cell proliferation GO:0042104 9.85 IGF1 IGF2 IGFBP2
25 activation of protein kinase B activity GO:0032148 9.85 IGF1 INS INSR
26 insulin-like growth factor receptor signaling pathway GO:0048009 9.85 AKT1 GHR IGF1 IGF1R IRS1
27 ERK1 and ERK2 cascade GO:0070371 9.84 EGF IGF1 ITGAV
28 glucose transport GO:0015758 9.84 AKT1 GH1 INS
29 regulation of glucose metabolic process GO:0010906 9.82 IGFBP3 IGFBP4 IGFBP5
30 positive regulation of glycolytic process GO:0045821 9.82 IGF1 INS INSR
31 cell-substrate adhesion GO:0031589 9.81 ITGA6 ITGAV ITGB3
32 cell adhesion mediated by integrin GO:0033627 9.81 ITGA6 ITGAV ITGB3
33 response to growth hormone GO:0060416 9.8 AKT1 GHR IGFBP5
34 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.8 GH1 IGF1 IGFBP3 IGFBP4 IGFBP5
35 positive regulation of glucose import GO:0046326 9.8 AKT1 AKT2 IGF1 INS INSR IRS1
36 positive regulation of insulin receptor signaling pathway GO:0046628 9.79 IGF2 INS IRS1
37 positive regulation of glucose metabolic process GO:0010907 9.77 AKT1 AKT2 IRS1
38 type B pancreatic cell proliferation GO:0044342 9.77 IGFBP3 IGFBP4 IGFBP5
39 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.73 ITGAV ITGB3
40 mammary gland epithelial cell differentiation GO:0060644 9.73 AKT1 AKT2
41 striated muscle cell differentiation GO:0051146 9.73 AKT1 IGFBP5
42 positive regulation of lipid biosynthetic process GO:0046889 9.73 AKT1 INS
43 positive regulation of fatty acid beta-oxidation GO:0032000 9.72 AKT2 IRS1
44 negative regulation of lipid storage GO:0010888 9.72 ITGAV ITGB3
45 growth hormone receptor signaling pathway GO:0060396 9.71 GH1 GHR
46 cell-substrate junction assembly GO:0007044 9.71 ITGA6 ITGB3
47 peripheral nervous system myelin maintenance GO:0032287 9.71 AKT1 AKT2
48 positive regulation of respiratory burst GO:0060267 9.7 INS INSR
49 apolipoprotein A-I-mediated signaling pathway GO:0038027 9.7 ITGAV ITGB3
50 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.69 AKT1 AKT2

Molecular functions related to Insulin-Like Growth Factor I according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.96 IGFBP1 IGFBP2 IGFBP4 IGFBP6 ITGAV
2 growth factor activity GO:0008083 9.85 EGF GH1 IGF1 IGF2
3 hormone activity GO:0005179 9.78 GH1 IGF1 IGF2 INS
4 insulin receptor binding GO:0005158 9.77 IGF1 IGF1R IGF2 INS IRS1
5 growth factor binding GO:0019838 9.73 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
6 insulin-like growth factor receptor binding GO:0005159 9.72 IGF1 IGF2 INS INSR IRS1
7 protein kinase C binding GO:0005080 9.71 AKT1 IRS1 ITGAV
8 fibronectin binding GO:0001968 9.71 IGFBP3 IGFBP5 ITGAV ITGB3
9 insulin-like growth factor binding GO:0005520 9.7 IGF1R IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5
10 insulin-like growth factor I binding GO:0031994 9.7 IGF1R IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5
11 phosphatidylinositol 3-kinase binding GO:0043548 9.63 IGF1R INSR IRS1
12 neuregulin binding GO:0038132 9.61 ITGA6 ITGAV ITGB3
13 insulin receptor substrate binding GO:0043560 9.57 IGF1R INSR
14 insulin binding GO:0043559 9.52 IGF1R INSR
15 C-X3-C chemokine binding GO:0019960 9.51 ITGAV ITGB3
16 insulin-like growth factor II binding GO:0031995 9.17 IGFBP1 IGFBP2 IGFBP3 IGFBP4 IGFBP5 IGFBP6
17 protein binding GO:0005515 10.45 AKT1 AKT2 EGF GH1 GHR IGF1

Sources for Insulin-Like Growth Factor I

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....